Clinical Trial Update: A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of different modified-release formulations of GSK221149 in healthy adult subjects has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation
• Preterm Labor

Drugs mentioned

• GSK221149

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obstetric Labour, Premature, Premature Ejaculation | Phase 1 | Status: TERMINATED